Eiger BioPharmaceuticals, Inc.
EIGR
Rank in Stocks
#36463
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
Share Price
$1.73
Last synced: 2025-06-17
Market Cap
$2.55M
Change (1 day)
-0.29%
Change (1 year)
-79.71%
Country
US
Trade Eiger BioPharmaceuticals, Inc. (EIGR)
Category
Healthcare
EPS for Eiger BioPharmaceuticals, Inc. (EIGR)
EPS as of December 2023 TTM: $-50.79
According to Eiger BioPharmaceuticals, Inc. latest financial reports and stock price the company's current EPS (TTM) is $-50.79. At the end of 2022 the company had a EPS of $-69.74 an increase over its 2021 EPS that were of $-29.98.
EPS history for Eiger BioPharmaceuticals, Inc. from 2016 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-50.79 | 0.02% |
| 2023 | $-50.78 | -27.19% |
| 2022 | $-69.74 | 132.62% |
| 2021 | $-29.98 | -56.76% |
| 2020 | $-69.34 | -25.04% |
| 2019 | $-92.50 | -19.31% |
| 2018 | $-114.63 | -21.43% |
| 2017 | $-145.90 | -37.96% |
| 2016 | $-235.16 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $17.32 | -134.10% |
US
|
|
| $-7.98 | -84.29% |
US
|
|
| $-5.29 | -89.58% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -154.62% |
NL
|
